Introduction
============

Heat shock protein 90 (HSP90) is a molecular chaperone family member that is crucial for the correct folding of many newly synthesized peptides and rematuration of denatured/misfolded client proteins. The client proteins of HSP90 are intensively involved in physiological, pathological and evolutionary processes [@B1]. Inhibition of HSP90 activity by small-molecule inhibitors has been demonstrated to cause potent reversal of diseases in the model of cancer, neurodegenerative disorders, epilepsy, infections and inflammatory diseases [@B2]. Although the role of HSP90 in metabolic diseases has gradually aroused people\'s concern [@B3]-[@B5], the underlying detailed mechanism, as well as the paralog specific roles remain elusive. The HSP90 family consists of four paralogs: *HSP90AA1, HSP90AB1, HSP90B1* (encoding glucose-regulated protein 94), and *TRAP1* (encoding TNF receptor-associated protein-1) [@B6]. Genetic evidences already suggest functional difference between HSP90α and HSP90β [@B7]. However, due to common location [@B8] and the high sequence identity between these two paralogs (85.8% identity and 93.4% similarity of amino acid sequence), it is rather difficult to distinguish their functional specialty through biological separation. Most of the pan-HSP90 inhibitors bind to the highly conserved N-terminal ATP binding domain (NTD). As a consequence, these pan-HSP90 inhibitors bind both HSP90α and HSP90β [@B9]. To interrogate the different functions of HSP90α and HSP90β, there is pressing need for the discovery of paralog-specific inhibitors.

Lipids are essential for energy homeostasis, reproductive and organ physiology and numerous aspects of cellular biology [@B10]. Dysregulation of lipid homeostasis leads to metabolic diseases, including obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases [@B11], [@B12]. Elevated peripheral non-esterified fatty acid (NEFA) pool and hepatic *de novo* lipogenesis (DNL) are key factors that contribute the lipid accumulation in the liver. Notably, in patients with non-alcoholic fatty liver disease (NAFLD), triglyceride turnover rates were not increased [@B13], while DNL accounts more than 20% of liver TG, 3-5 times higher than healthy populations [@B14], [@B15]. Thus, targeting DNL is a potent strategy to develop medications treating metabolic diseases [@B16], [@B17]. Sterol regulatory element-binding proteins (SREBPs) are major regulators of DNL that control the expression of genes involved in the biosynthesis and uptake of fatty acids, triglycerides, cholesterol and phospholipids [@B18], [@B19]. Even though a previous report has already shown that inhibition of HSP90 by 17-AAG modulates lipid homeostasis *via* SREBP pathway [@B20], the clinical and mechanical relevance between HSP90 paralogs and lipid disorders remains largely elusive. Moreover, 17-AAG, as a pan-inhibitor of HSP90, has a wide range of effects on their clients and shows some serious side effects, such as primarily diarrhea, fatigue and hepatotoxicity [@B21]. This makes 17-AAG unsuitable for long-term treatment of chronic diseases, such as metabolic diseases. Therefore, the search for HSP90 inhibitors with lower toxicity has become a new strategy for the treatment of metabolic disorders.

In this study, we found that HSP90β, rather than HSP90α, is clinical relevant to lipid dysregulation in NAFLD patients and animal models. It was demonstrated that HSP90β is vital in regulating fatty acid and cholesterol metabolism. Mechanistically, HSP90β promotes mSREBPs ubiquitination and, thus, increasing proteasomal degradation dependent on Akt-GSK3β-FBW7 pathway. Corylin, a natural product from the fruits of *Psoralea corylifolia* Linn., was identified as a novel selective HSP90β inhibitor. *In vivo*, corylin treatment reduced body weight gain and ameliorated hyperlipidemia, insulin resistance and atherosclerosis. Overall, these results suggest that inhibiting HSP90β may be a potential therapeutic treatment of lipid disorders and corylin may become a promising lead compound to treat obesity-induced fatty liver disease, type 2 diabetes and atherosclerosis.

Materials and Methods
=====================

Cell culture
------------

HEK293T cell lines (293T cells) were obtained from the American Type Culture Collection. HL-7702 cells were purchased from Keygen Biotech (Nanjing, China). Both of the cell lines were grown in medium B under 37 °C, 5% CO~2~. HH (Human Hepatocytes) cells were purchased from ScienCell Research Laboratories (San Diego, CA, USA) and were cultured in 10 cm^2^ flask coated with poly-L-lysine in medium E.

Animal experiments
------------------

The laboratory animal facility in the animal experimental center has been accredited by Association for Assessment and Accreditation of Laboratory Animal Care International. All experiments and animal care in this study were conducted in accordance with the national and international directives (the Provision and General Recommendation of Chinese Experimental Animals Administration Legislation and Guide for the Care and Use of Laboratory Animals, United States National Research Council, 2011) and approved by the Science and Technology Department of Jiangsu Province (SYXK (SU) 2016-0011). The C57BJ/6L and ApoE^-/-^ mice (SPF grade, six weeks old, 20\~24 g) were purchased from Nanjing University (Nanjing, China). The animals were kept under a consistent temperature (24 °C) with 12 h light/dark cycle and fed standard food pellets with access to sterile water *ad libitum*. HFD was contained 60% fat, 20.6% carbohydrate and 19.4% protein w/w. WD for lipid disorder was contained 20% fat, 1.25% cholesterol, 0.5% cholic acid w/w. WD for atherosclerosis contained 60% fat, 20.6% carbohydrate, 1.25% cholesterol and 19.4% protein w/w.

Human nonalcoholic fatty liver and normal healthy liver samples
---------------------------------------------------------------

Human liver samples from patients with NAFLD who underwent liver biopsy, resection. Nonalcoholic fatty liver was diagnosed by abdominal ultrasound and was verified according to liver histology. The liver samples were from treatment naïve patients following bariatric surgery to rule out the possibility that medication could complicate the experimental results. Normal human liver tissue was the non-involved surrounding tissue, obtained from NAFLD-free donors undergoing partial hepatectomy for hepatocarcinoma. The information of NAFLD-free donors was listed in Supplementary Table [1](#SM0){ref-type="supplementary-material"}. An informed consent in writing was obtained from each patient and the study protocol was conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the IRB.

Statistical analysis
--------------------

All data are expressed as the means standard error (SE). Statistical significance was calculated by student\'s *t*-test, one-way ANOVA or two-way ANOVA. When ANOVA indicated a significant difference among the groups, the statistical difference between two groups was compared using a stricter criterion for statistical significance. Differences with p \<0.05 were considered to be statistically significant (p\*\<0.05, p\*\*\<0.01, p\*\*\*\<0.001, NS=Non-significant).

Additional methods
------------------

Detailed materials and methods are available in the supplemental data.

Results
=======

The expression of HSP90β, rather than HSP90α, was upregulated in the non-alcoholic fatty liver disease
------------------------------------------------------------------------------------------------------

To evaluate potential role of HSP90 in the pathogenesis of lipid metabolic disorders, we measured the hepatic HSP90α and HSP90β levels in human specimens from 20 subjects with NAFLD (Table [S1](#SM0){ref-type="supplementary-material"}). HSP90β in the liver of NAFLD was higher compared with that in healthy donors, while HSP90α remained unchanged (Figure [1](#F1){ref-type="fig"}A). Serum total triglyceride (TG) and cholesterol (TC) concentration had high-positive correlation with HSP90β expression (*R*=0.4386, *P*\<0.01;*R*=0.2066, *P*\<0.05, respectively) (Figure [1](#F1){ref-type="fig"}B). No correlation between blood glucose or insulin and HSP90β was observed (Figure [1](#F1){ref-type="fig"}B). In contrast, there were no correlations between HSP90α level and these clinical parameters (Figure [1](#F1){ref-type="fig"}B). Next, the expression of these two HSP90s in diet induced obese mice and in *ob/ob* mice was checked. We observed that the hepatic mRNA and protein level of *HSP90AB1*, but not *HSP90AA1*, was largely increased in high fat diet (HFD)-fed mouse liver (Figure [1](#F1){ref-type="fig"}C-F), as well as in *ob/ob* mice (Figure [1](#F1){ref-type="fig"}G-J). All together, these results suggest that HSP90β, rather than HSP90α, is correlated with lipid dysregulation in NAFLD.

Knockdown of HSP90β improves lipid homeostasis through inhibiting *de novo* lipid biogenesis
--------------------------------------------------------------------------------------------

To check whether modulation of HSP90 paralogs indeed regulates lipid homeostasis, HL-7702 hepatocytes were transfected with HSP90 siRNAs (Figure [2](#F2){ref-type="fig"}A) or overexpression plasmids (Figure [2](#F2){ref-type="fig"}B). Knockdown of HSP90β reduced 21% of cellular TG and 33% of TC (Figure [2](#F2){ref-type="fig"}A). On the contrary, overexpression of HSP90β increased 24% of TG and 22% of TC (Figure [2](#F2){ref-type="fig"}B). By contrast, modulating HSP90α did not affect lipid contents (Figure [2](#F2){ref-type="fig"}A-B). Nile-Red and filipin staining gave the same results (Figure [2](#F2){ref-type="fig"}C). Moreover, knockdown of HSP90β significantly inhibited the *de novo* synthesis of both cholesterol and fatty acid in hepatic cells (Figure [2](#F2){ref-type="fig"}D).

To verify the *in vivo* role of HSP90β in regulating lipid homeostasis, adenoviruses carrying HSP90β-shRNA were injected into HFD-fed mice *via* the tail vein, leading to an 80% decrease of hepatic HSP90β (Figure [2](#F2){ref-type="fig"}E). Simultaneously, the expression of HSP90α was not affected (Figure [2](#F2){ref-type="fig"}E). In the absence of significant differences in dietary intake (Figure [2](#F2){ref-type="fig"}F), the body weight was about 16% lower than that in the LacZ-shRNA group, after injection of adv-shHSP90β for 2 weeks (Figure [2](#F2){ref-type="fig"}G). After HSP90β was knocked down, the levels of serum TC and TG were reduced by 13.2% and 19.0% respectively, but high-density lipoprotein cholesterol (HDL-c) increased about 46.1% (Figure [2](#F2){ref-type="fig"}H). The level of serum low-density lipoprotein cholesterol (LDL-c) was also decreased by 13.5% (Figure [2](#F2){ref-type="fig"}H). Albeit no significant difference in liver weight between the two groups (Figure [2](#F2){ref-type="fig"}J), a 30.0% decrease in hepatic TC and a 49.3% decrease of TG were observed (Figure [2](#F2){ref-type="fig"}K). Clearly, this change was not due to increasing fecal excretion of TC or TG (Figure [2](#F2){ref-type="fig"}L). Consistently, the size of hepatic lipid droplets dramatically decreased in HSP90β knockdown mice (Figure [2](#F2){ref-type="fig"}I). The expression of genes involved in the biosynthesis of cholesterol, fatty acid and triglycerides were lower in HSP90β knockdown mice (Figure [2](#F2){ref-type="fig"}M). While the expression of genes involved in VLDL secretion, cholesterol efflux and fatty acid oxidation was not significantly changed (Figure [2](#F2){ref-type="fig"}M). Therefore, we reasoned that the knockdown of HSP90β improves lipid homeostasis, most probably through inhibiting DNL.

HSP90 have a plethora of client proteins [@B22]. For example, in adipocytes, HSP90 chaperones PPARγ to facilitate adipocytes survival and differentiation [@B4]. Indeed, we observed a reduction of cell size in adipose tissues in adv-shHSP90β treated mice (Figure [S1](#SM0){ref-type="supplementary-material"}A). TNF-α and IL-6 expression did not change, suggesting there is no inflammation (Figure [S1](#SM0){ref-type="supplementary-material"}B). We did not observe changes of browning and lipid metabolism related genes in BAT and WAT (Figure [S1](#SM0){ref-type="supplementary-material"}B). It is possible that HSP90α and HSP90β may recognize and selective bind to different client proteins. Through Hsp90Int.DB website database query and alignment, we found that GZMA and H2AFX are specific client proteins for HSP90α, but not regulated by HSP90β [@B23], [@B24]. Thus, only when HSP90α was knocked down, the levels of GZMA and H2AFX proteins were decreased (Figure [S2](#SM0){ref-type="supplementary-material"}). The functional difference of HSP90 paralogs might attribute to the difference of their client proteins.

Corylin is a specific inhibitor of HSP90β
-----------------------------------------

The above results suggested that selectively inhibiting HSP90β may be a potential therapeutic strategy for lipid disorders. As the discovery of HSP90β specific inhibitors is not satisfying [@B29], we decided to use new tactics. We performed virtue screening to search compounds that have higher binding affinity to HSP90β (PDB ID code 3PRY) than to HSP90α (3Q6M). From a structure database of around 3000 in-house natural compound library, we found 12 compounds with the big difference in the binding energy between HSP90β and HSP90α. The effects on SREBP activity of these compounds were further evaluated (Table [S2](#SM0){ref-type="supplementary-material"}). It turned out that 9 out of 12 of the compounds exhibited SREBPs inhibitory effects, suggesting paralog specific inhibition of HSP90β might particularly affect SREBP activity. Among these compounds, corylin exhibited highest SREBP inhibitory effects (Table [S2](#SM0){ref-type="supplementary-material"}). Next, we used photo-affinity labelling and pull-down experiments to identify the interaction proteins to corylin [@B30]. According to the experiment reproducibility (p\<0.05) and the enrichment of proteins (\>1.2 fold enrichment) by corylin-agarose beads, we finally focused on three proteins (HSP90β, HSP90α and ENO1) (Table [S3](#SM0){ref-type="supplementary-material"}). The binding affinity of corylin to these three proteins was then analyzed using microscale thermophoresis (MST) assay [@B31]. The *K*~D~ between corylin and HSP90β was 24.65 ± 10.16 nM, much lower than that of 17-AAG (Figure [4](#F4){ref-type="fig"}A and Figure [S4](#SM0){ref-type="supplementary-material"}A-B). 17-AAG, but not corylin bound with HSP90α (Figure [S4](#SM0){ref-type="supplementary-material"}C-D). AP-III-a4 (a specific inhibitor of ENO1), but not corylin bound with ENO1 (Figure [S4](#SM0){ref-type="supplementary-material"}E-F). Collectively, the above results clearly indicate that the binding of corylin to HSP90β is specific. Consistently, the inhibitory effects of corylin on SREBPs activity were reversed by overexpression of HSP90β (Figure [S5](#SM0){ref-type="supplementary-material"}A-C), but not HSP90α or ENO1 (Figure [S5](#SM0){ref-type="supplementary-material"}D-E). 17-AAG binds to the NTD of HSP90, while, corylin did not bind to the NTD (1-217), the charged linker domain (218-276) and the C-terminal domain (CTD) (Figure [4](#F4){ref-type="fig"}A and Figure [S6](#SM0){ref-type="supplementary-material"}A-F). Residues between 276 and 602 are crucial for corylin binding (Figure [4](#F4){ref-type="fig"}A and Figure [S6](#SM0){ref-type="supplementary-material"}G-H). 17-AAG and XL-888, but not corylin, significantly inhibited the ATPase activity of HSP90β (Figure [S7](#SM0){ref-type="supplementary-material"}A), consistent with the binding data (Figure [4](#F4){ref-type="fig"}A). Next, we identified a single potential binding pocket located around residues 312 to 439 in the MD of HSP90β using Autodock (Figure [4](#F4){ref-type="fig"}B), a pocket that is distinguishable from HSP90α [@B32]. The binding energy between HSP90β and corylin is -10.5 KJ/mol. In contrast, the binding of HSP90α and corylin is poor (-5.0 KJ/mol), which is similar to the results using Glide 6.9 (Table [S2](#SM0){ref-type="supplementary-material"}). More specifically, we found three hydrogen bonds formed between the amino acid residues of HSP90β MD and corylin based on surface topography and sequence of HSP90β. Two hydrogen bonds are predicted to form between the phenolic hydroxyl group and amino acids N375 and N436. Another hydrogen bond is formed between carbonyl group and W312 (Figure [4](#F4){ref-type="fig"}B). The residues W312, N375 and N436 were then mutated to alanine to prevent hydrogen bond formation, consequently, the mutated HSP90β no longer bound to corylin (Figure [4](#F4){ref-type="fig"}A and Figure [S6](#SM0){ref-type="supplementary-material"}I). By contrast, the point mutations did not influence the interaction between HSP90β and 17-AAG (Figure [4](#F4){ref-type="fig"}A and Figure [S6](#SM0){ref-type="supplementary-material"}J). Consistently, either mutation in these three amino acids, or corylin treatment, did not affect HSP90β ATPase activity (Figure [S7](#SM0){ref-type="supplementary-material"}B). When corylin was modified to neobavaisoflavone, the binding affinity was only slightly reduced (Figure [4](#F4){ref-type="fig"}C and Figure [S6](#SM0){ref-type="supplementary-material"}K). When phenolic hydroxyl group was converted to methoxy group (compound A, Figure [4](#F4){ref-type="fig"}C), the binding to HSP90β was significantly weakened (Figure [4](#F4){ref-type="fig"}C and Figure [S6](#SM0){ref-type="supplementary-material"}L). Consistently, the effect on SREBP activity of neobavaisoflavone was similar as corylin, while compound A no longer affected the abundance and transcriptional activity of SREBPs (Figure [4](#F4){ref-type="fig"}M and N). Thus, we concluded that the residues W312, N375 and N436 of HSP90β are essential for corylin binding.

Corylin inhibits *de novo* lipid synthesis by promoting mSREBPs ubiquitination and proteasomal degradation
----------------------------------------------------------------------------------------------------------

Corylin did not cause obvious hepatic toxicity (Figure [5](#F5){ref-type="fig"}A). In contrast, a series of pan-HSP90 inhibitors exhibited severe hepatic toxicity (Figure [5](#F5){ref-type="fig"}A). This is probably due to inhibition of HSP90α, since knockdown of HSP90α led to cell death (Figure [S8](#SM0){ref-type="supplementary-material"}A). Corylin treatment impaired the levels of mSREBP-1 and -2 in time- and dose- dependent manners (Figure [5](#F5){ref-type="fig"}B). Nevertheless, ATF6, a transcription factor with similar processing route as SREBPs, was not affected by corylin (Figure [S8](#SM0){ref-type="supplementary-material"}B), suggesting that the effect of corylin on SREBPs is specific. As corylin reduced the mSREBPs in the nucleus (Figure [S8](#SM0){ref-type="supplementary-material"}C), the expression of their target genes was significantly reduced (Figure [5](#F5){ref-type="fig"}C-D). These results were reproducible in human primary hepatocytes (Figure [S9](#SM0){ref-type="supplementary-material"}A-D). Consistently, DNL was significantly attenuated by corylin (Figure [5](#F5){ref-type="fig"}E). Furthermore, corylin largely reduced cellular cholesterol and neutral lipids level (Figure [S8](#SM0){ref-type="supplementary-material"}D).

In HSP90β knockout hepatocytes (KO cells), corylin no longer influenced mSREBPs (Figure [S10](#SM0){ref-type="supplementary-material"}A). KO cells got sensitive to corylin when wild-type HSP90β, but not triple mutant (W312A/N375A/N436A) HSP90β was put back (Figure [S10](#SM0){ref-type="supplementary-material"}B). Corylin decreased endogenous and exogenous mSREBPs (Figure [S10](#SM0){ref-type="supplementary-material"}C) through increased ubiquitination (Figure [S10](#SM0){ref-type="supplementary-material"}D) and accelerated degradation (Figure [S10](#SM0){ref-type="supplementary-material"}E and F). These effects were blocked by the proteasome inhibitor MG-132 (Figure [S10](#SM0){ref-type="supplementary-material"}G) or by FBW7 siRNAs (Figure [S10](#SM0){ref-type="supplementary-material"}H-I). Corylin disrupted the binding of HSP90β with Akt (Figure [5](#F5){ref-type="fig"}F) and significantly reduced Thr308 phosphorylation of Akt and Ser9 phosphorylation of GSK3β in a time- and dose-dependent manner (Figure [S10](#SM0){ref-type="supplementary-material"}K-L). Notably, in HSP90β KO cells, insulin no longer increased T308 phosphorylation, but still increased S473 phosphorylation. T308 dephosphorylation by corylin decreased \~55% of Akt activity, a much weaker effect than 17-AAG that inhibited \~80% of Akt activity (Figure [S11](#SM0){ref-type="supplementary-material"}). GSK3β S9 phosphorylation and mature form of SREBP-1c were downregulated in insulin treated HSP90β KO cells (Figure [S10](#SM0){ref-type="supplementary-material"}J). These data suggest that HSP90β is involved in insulin stimulated Akt activation, subsequently affect GSK3β-SREBPs and lipid biosynthesis in hepatocytes. Meanwhile, the decreased levels of mSREBPs was reversed by the GSK3β inhibitors SB216763 (Figure [5](#F5){ref-type="fig"}G), CHIR9902 (Figure [5](#F5){ref-type="fig"}H), or GSK3β siRNAs (Figure [5](#F5){ref-type="fig"}I and Figure [S12](#SM0){ref-type="supplementary-material"}A). Overexpression of Akt also blocked the effect of corylin on mSREBPs (Figure [5](#F5){ref-type="fig"}J and Figure [S12](#SM0){ref-type="supplementary-material"}B-D). Taken together, these data demonstrated that corylin, as a specific inhibitor of HSP90β, promotes mSREBPs ubiquitination and proteasomal degradation through the Akt-GSK3β-FWB7 pathway.

Corylin improves lipid homeostasis and insulin resistance
---------------------------------------------------------

Next, we investigated the effect of corylin on obesity *in vivo*. The bodyweight of mice fed with western-type diet (WD) plus corylin (15 mg/kg/day and 30 mg/kg/day, respectively) or lovastatin (30 mg/kg/day) was lighter than that of vehicle treated WD mice while the food intake remained almost unchanged (Figure [6](#F6){ref-type="fig"}A). Meanwhile, the fat/lean or fat/whole-body ratio dropped more than 50% in the same dosage (30 mg/kg/day) of corylin- or lovastatin-treated mice (Figure [6](#F6){ref-type="fig"}B). Corylin or lovastatin significantly reduced the level of serum TC, TG and LDL-c, and increased the level of HDL-c (Figure [6](#F6){ref-type="fig"}C). The liver weight, hepatic TC and TG in corylin-treated mice were notably lower than those of the vehicle-treated mice (Figure [6](#F6){ref-type="fig"}D and E). Corylin significantly decreased the level of serum AST in WD-fed mice. No significant difference but reduced ALT level was detected in WD-fed mice with corylin (Figure [6](#F6){ref-type="fig"}F). Corylin at 30 mg/kg/day dramatically reduced the cell sizes of both white adipose tissue (WAT) and brown adipose tissue (BAT) in WD-fed mice. The contents of lipids were decreased in the livers of corylin-treated mice (Figure [6](#F6){ref-type="fig"}G). Similar body weight lowering effects were observed in HFD-fed mice (Figure [S13](#SM0){ref-type="supplementary-material"}A). Notably, there was no significant difference in food intake (Figure [S13](#SM0){ref-type="supplementary-material"}B), faecal cholesterol or triglyceride content (Figure [S13](#SM0){ref-type="supplementary-material"}C-D). Corylin treatment did not increase cold resistance in HFD-fed mice when exposed to cold (Figure [S13](#SM0){ref-type="supplementary-material"}E). The energy expenditure was then measured for 24 h under a 12 h light-day cycle. Interestingly, although no significant difference was observed at night between the HFD-fed mice and HFD plus corylin-fed mice, the O~2~ consumption and energy expenditure (EE) were significantly increased during the day (Figure [S13](#SM0){ref-type="supplementary-material"}F-H). The EE increase also contributed, at least partially, to the body weight loss in HFD-fed mice. Weight reduction is considered to be beneficial for improving insulin resistance. Next, we investigated whether corylin improves insulin resistance *in vivo*. Corylin significantly blunted the elevated fasting blood glucose and insulin level (Figure [S14](#SM0){ref-type="supplementary-material"}A-B) and improves the glucose and insulin intolerance (Figure [S14](#SM0){ref-type="supplementary-material"}C-D) in WD-fed mice. Consistent with the *in vitro* results, corylin reduced the level of mSREBPs in the liver of WD-fed mice (Figure [S14](#SM0){ref-type="supplementary-material"}E-F). Most of SREBP-1 and SREBP-2 target genes were significantly downregulated in the liver of WD-fed mice by corylin (Figure [S14](#SM0){ref-type="supplementary-material"}G-I). In hepatocytes, as well as in mice livers, corylin neither increases LXR target gene expression, nor activates ER stress genes expression (Figure [S15](#SM0){ref-type="supplementary-material"}). We also found that the expression of VLDL secretion, cholesterol efflux, fatty acid oxidation, adipocyte browning, and glucose uptake were not significantly changed (Figure [S16](#SM0){ref-type="supplementary-material"}).

To address the question whether corylin improves liver metabolism through inhibiting HSP90β, we treated HFD-fed mice with corylin for 4 weeks, then adenoviral virus expressing HSP90β or control were injected. Overexpression of HSP90β reversed the corylin effects on SREBPs and their target gene expression (Figure [S17](#SM0){ref-type="supplementary-material"}A-H). HSP90β also reversed lipid parameters that were improved by corylin (Figure [S17](#SM0){ref-type="supplementary-material"}I-M). In summary, corylin inhibits SREBPs and improves lipid homeostasis *in vivo* through inhibiting HSP90β.

Corylin decreases atherosclerosis development
---------------------------------------------

The effect of corylin on atherosclerotic lesion formation was further explored in ApoE^-/-^ mice. Corylin treatment did not cause obvious toxicity and difference in food intake (Figure [7](#F7){ref-type="fig"}A), but reduced the weight gain at high dose (Figure [7](#F7){ref-type="fig"}B). Both corylin and lovastatin treatment made the plasma transparent, indicating reduced lipid content (Figure [7](#F7){ref-type="fig"}C). Moreover, corylin or lovastatin obviously decreased TC, TG and LDL-c levels and elevate HDL-c levels in plasma (Figure [7](#F7){ref-type="fig"}D). Corylin reduced the number and size of aortic plaques in WD-fed ApoE^-/-^ (Figure [7](#F7){ref-type="fig"}E and F). Particularly, the areas of the lesion in the thoracic aorta and abdominal aorta were significantly smaller (Figure [7](#F7){ref-type="fig"}G-I). The lesion areas in cross-sections of the aortic sinus in the corylin-treated mice were reduced dramatically (Figure [S18](#SM0){ref-type="supplementary-material"}A). The activated endothelial cells marker VCAM-1 was reduced in corylin-treated mice (Figure [S18](#SM0){ref-type="supplementary-material"}B). Upon corylin treatment, the expression of *HSP90AB1* and *HSP90AA1* remained unchanged, while *SREBPs* and their target genes involved in lipid synthesis were downregulated (Figure [7](#F7){ref-type="fig"}J). In contrast, *HMGCR*, *HMGCS* and *FASN* were dramatically upregulated by lovastatin (Figure [7](#F7){ref-type="fig"}J). These results demonstrated that corylin ameliorates atherosclerosis lesion formation of plaques in the aortic root in WD-fed ApoE^-/-^ mice without increasing fatty acid synthesis, a feature superior to lovastatin.

Discussion
==========

In this report, we have demonstrated the clinical significance of the expression of HSP90β in NAFLD patients. Further, a novel paralog-specific HSP90 inhibitor, corylin has been identified. Genetic targeting or pharmacologic inhibition of HSP90β leads to degradation of SREBPs *via* Akt-GSK3β-FBW7 pathway, thus improves lipid homeostasis.

To date, the paralog-specific role of HSP90 in the liver is little known. In this study, we observed HSP90β, instead of HSP90α, obviously increases in the liver of human NAFLD patients and obesity- induced fatty liver mice (Figure [1](#F1){ref-type="fig"}). Further studies indicate that HSP90β plays a paralog-specific role in regulating lipid homeostasis. Our results help researchers to understand the role of different paralogs of HSP90 in lipid metabolism, and promote HSP90β as a drug target for the treatment of lipid disorders. Chemical compounds that specifically inhibit HSP90β certainly satisfy the demand of precise medical treatment for lipid disorders. The NTD with ATP pocket- and CTD with novobiocin-binding site of HSP90 are under intense study and therefore attract most interest in drug discovery. Small compounds such as 17-allylaminogeldamamycin (17-AAG), ganetespib (STA-9090), SNX-2112 and novobiocin have been developed accordingly [@B33]. The NTD is not only homology to HSP90 chaperone family members, but also to members of the gyrase-Hsp90-histidine kinase-MutL (GHKL) group within the ATPase/ kinase superfamily [@B34]. Similarly, the CTD contains a second ATP binding site, which can be competed with novobiocin, cisplatin, epilgallocatechin-3-gallate (EGCG) and taxol [@B35]. These two binding domains are closely related to cell proliferation and tumor progression [@B36]. Similar as other drugs targeting ATP/ADP binding pocket, the off-target effects hampered the development of the first generation geldanamycins that exerted significant toxicities [@B37], [@B38]. Indeed, we observed cytotoxicity of these compounds in hepatocytes (Figure [5](#F5){ref-type="fig"}A). Corylin binds to HSP90β in a unique pocket located in the middle domain formed by amino acids W312/N375/N436, notably, either mutation in these three amino acids, or corylin treatment, did not affect HSP90β ATPase activity (Figure [S7](#SM0){ref-type="supplementary-material"}B). The *K~D~* of corylin with HSP90β was 24.65 ± 10.16 nM, the highest binding affinity ever reported. Therefore, corylin is the small molecule that distinguishes HSP90α and HSP90β. With this paralog-specific inhibitor, less cytotoxicity was observed (Figure [5](#F5){ref-type="fig"}A) and further understanding of the biologic function of this chaperone family is warranted.

In this study, we found genetic deletion or pharmacological inhibition of HSP90β caused the Thr308 dephosphorylation of Akt (Figure [S2](#SM0){ref-type="supplementary-material"}F, Figure [S10](#SM0){ref-type="supplementary-material"}J-L). Akt full activation needs both T308 in the catalytic domain and S473 in the carboxy-terminal noncatalytic region [@B39]. It is reported that either T308 or S473 mutation leads to diminished Akt activity, although T308 mutation seems to cause more severe effect [@B40]. The downstream Akt targets are affected differently by Akt mutations. For example, it has been shown that genetic ablation of mTORC2 components (rictor, mLST8 or sin1) abolished S473 phosphorylation and only affected a subset of Akt targets *in vivo*, including FoxO1/3a, while other Akt targets, TSC2, GSK3, S6K and 4E-BP1 were unaffected [@B41]. As in our case, we found that genetic or pharmacologic inhibition of HSP90β caused T308 dephosphorylation. T308 dephosphorylation by corylin decreased \~55% of Akt activity, a much weaker effect than 17-AAG that inhibited \~80 % of Akt activity (Figure [S16](#SM0){ref-type="supplementary-material"}). Subsequently, GSK3β was then activated and stimulated SREBP degradation (Figure [S2](#SM0){ref-type="supplementary-material"}F and Figure [S10](#SM0){ref-type="supplementary-material"}). The effect could rather be a result of changes in overall Akt activity change than S473 phosphorylation, since T308 and S473 phosphorylation could be separated regulated [@B41]. As corylin decreased T308 without affecting S473 very much, it could be a good tool to study mTORC2 independent Akt regulation.

Previous reports used pan-HSP90 inhibitor 17-AAG or its analogues to study the function role of HSP90 in different disease models [@B42]. As 17-AAG binds both HSP90α and HSP90β, meanwhile, there is no HSP90β-flox mice available (HSP90β KO mice are lethal), the HSP90β specific role in physiological and pathological conditions remain largely unknown. With HSP90β specific inhibitor corylin, HSP90β specific roles in these diseases could be re-examined. It should also be noted that although alcoholic fatty liver disease (AFLD) and NAFLD share similar pathological spectra, these two diseases differ from each other not only in terms of clinical features and patient outcomes [@B43], but also in terms of underlying mechanisms [@B44]. Notably, chemicals that protects against ethanol induced liver injury, such as silymarin [@B45], not necessarily alleviated NAFLD and vice versa [@B46]. Whether inhibition of HSP90β in AFLD models also decreased alcohol mediated oxidative stress, reduced serum endotoxin, decreased inflammatory responses in hepatic macrophages, deserve further study.

In the last decades, the lab of Brown and Goldstein has discovered that SREBPs are master regulators of *de novo* lipogenesis [@B18], [@B47]. These studies suggest that selective inhibition of SREBPs might constitute a new class of drugs against lipid disorders, as well as type 2 diabetes. However, the inhibitors of SREBPs processing, such as 25-HC, activate LXR and induce ER stress, leading to hepatic steatosis and insulin resistance [@B48], [@B49]. Corylin suppressed SREBPs activity in a different mechanism. It selectively inhibits HSP90β and promotes SREBPs degradation depending on Akt-GSK3β-FBW7 pathway (Figure [4](#F4){ref-type="fig"} and Figure [S2](#SM0){ref-type="supplementary-material"} and Figure [S10](#SM0){ref-type="supplementary-material"}), without affect LXR target genes and ER stress gene expression. In animal experiments, corylin alleviates hepatic steatosis and hyperglycemia (Figure [6](#F6){ref-type="fig"}G), insulin resistance (Figure [S14](#SM0){ref-type="supplementary-material"}A-D). These data suggested that corylin has an incomparable advantage in the treatment of lipid disorders. In a previous study [@B50], it shows that corylin was subjected to massive first-pass metabolism in liver and intestine. Therefore, we supposed that liver is the major organ that responsible for the beneficial effects of corylin.

We believe our findings pave the way for future investigation on the paralog-specific roles of HSP90α and HSP90β in different physiological and pathological conditions. In the obese animals, both mRNA and protein level of *HSP90AB1* is increased. Therefore, unraveling the different molecular mechanisms that activate HSP90 paralogs is very important to advance the understanding of HSP90 functions, thus to improve the therapeutic effects in metabolic disease, cancer, neurodegeneration diseases, eplipsy, etc.
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![**The Level of HSP90 paralogs in the Liver of Obese Mice and NAFLD Patients. (**A) The immunohistochemistry staining of HSP90β or HSP90α in the liver of healthy donors (n=5) and NAFLD patients (n=20). (B) The correlation between immunostaining signal of HSP90s and the clinical parameters including serum level of glucose, insulin, TG and TC (n=20). (C, D, G, H) Liver sections of HFD-induced obese mice (C, D) or *ob/ob* mice (G, H) were stained with HSP90 paralog specific antibodies. (D and H) The mRNA level of *HSP90AB1* or *HSP90AA1* in the liver was analyzed in HFD- induced obese mice (E) and *ob/ob* mice (I), respectively. n = 9 for chow group or HFD group; n = 14 for WT mice group, n = 8 for *ob/ob* mice group. (F and J) The protein level of HSP90α or HSP90β in the liver was analyzed by western blot in HFD- induced obese mice (E) and *ob/ob* mice (I), respectively. Error bars are represented as mean ± SEM. The Pearson correlation coefficient is used to test the correlation between HSP90 paralogs expression and clinical parameters (B). Student *t*-test was used to analyze significance between two sets of data (D and F). \*\*\*p \< 0.001 *vs* chow diet mice or WT mice.](thnov09p5769g001){#F1}

![**Knockdown of HSP90β Improves Lipid Homeostasis.** (A and B) The cellular TG and TC levels were measured in human liver HL-7702 hepatocytes transfected with siRNA targeting HSP90β or HSP90α (A) or overexpression (OE) of HSP90β (3.6 times) or HSP90α (4.2 times) (B), the effect of interference or overexpression was verified by western blot. (C) The siRNA treated HL-7702 hepatocytes incubated in medium B for 48 h, and then switched to medium D for another 24 h. The cells then were stained with Nile-Red, which specifically recognizes neutral lipids or filipin, which definitely binds free cholesterol. (D) HL-7702 hepatocytes were incubated in medium B treating with indicated concentrations of siRNA HSP90β for 48 h, and then switched to medium D for another 24 h. Acetic acid sodium salt 1-^14^C was directly added into the medium and incubated for additional 2 h. The radioactive products were identified by comparison with unlabeled standards and visualized with iodine vapor. (E-L) Male C57BL/6J mice (6 weeks) were randomly grouped (10 mice each group). Mice were allowed *ad libitum* access to water and high fat diet (HFD). After four weeks, mice were intravenously injected with titer of 5×10^9^ adenovirus expressing the shRNA targeting HSP90β or the shRNA targeting LacZ. HFD was still administrated to mice for additional 14 days. Then, mice were sacrificed and subjected to various analysis. (E) The total protein from mice liver were prepared, and subjected to immunoblot analysis. Statistical analysis of hepatic HSP90β protein level in panel E normalized to Actin. (F) Food intake during the six week treatment. (G) Body weight measurement during the six weeks treatment. (H) The effect of HSP90β knockdown on serum TG, TC, HDL-c and LDL-c levels. (I) Oil red staining of liver sections. (J) The weight of liver. (K) The TC and TG level in the liver. (L) The TC and TG in the feces were analyzed by GC-MS. (M) Lipid mebabolism related genes expression was detected by q-RT-PCR. Mouse GAPDH was used as the internal control. Error bars are represented as mean ± SEM. Statistical analysis was done with one-way ANOVA (Dunnett\'s post test) (A, B and C), two-way ANOVA (Bonferroni\'s test) (F and G), or student\'s *t*-test (E, H, J, K, and L). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 *vs* control vector, control adenovirus or control siRNA.](thnov09p5769g002){#F2}

![**HSP90β Regulates *de novo* Lipid Synthesis through Promoting the mSREBPs Ubiquitination and Proteasomal degradation.** (A) HL-7702/SRE-Luc cells were incubated in medium B and treated with indicated siRNA for 48 h, the cells were then switched to medium D or medium D containing 25-HC (2 μg/ml) for 4 h. After the treatment, cells were lysed and luciferase activity was measured. (B and C) HL-7702 hepatocytes were incubated in medium B and treated with indicated siRNA for 48 h, the cells were then switched to medium D or medium D containing 25-HC (2 μg/ml) for 4 h. After the treatment, (B) the whole cell extracts underwent immunoblotting with indicated antibodies. P represents precursor SREBP and m represents mSREBP. (C) The expression of various genes was analyzed by qRT-PCR. Human GAPDH was used as the control. (D) The HL-7702/WT and HL-7702/KO HSP90β cells were depleted of sterols by incubating in medium D for 24 h, the total protein of cells were prepared and subjected to immunoblotting with indicated antibodies. (E and F) HL-7702 hepatocytes were transfected with myc-HSP90β (3.4 times) for 24 h, and then depleted of sterols by incubating in medium D for another 24 h, (E) the whole cell extracts underwent immunoblotting with indicated antibodies. (F) The expression of various genes was analyzed by qRT-PCR. Human GAPDH was used as the internal control. (G and H) HL-7702 hepatocytes were transfected with flag-mSREBP-1 (G) or flag-mSREBP-2 (H) plasmids and cultured for 24 h. The cells were switched to medium D for another 24 h, the whole cell extracts underwent immunoblotting with indicated antibodies. (I and J) HL-7702 hepatocytes were transfected with flag-mSREBP-1 plasmid and siRNA against HSP90β for 48 h (I). HL-7702 hepatocytes were transfected with flag-mSREBP-2 plasmid and siRNA HSP90β for 48 h (J). After adding 50 µM cycloheximide for 1 h, the whole cell extracts were harvested after incubation for indicated periods of time, mSREBPs were detected by immunoblotting with indicated antibodies. The graph depicted the averaged ratio of the autoradiographic signals of flag to actin levels, the dotted lines show the half-life of flag-mSREBP-1/-2. (K) HL-7702 hepatocytes were transfected with indicated siRNA for 48 h. The cells were switched to medium D containing MG-132 for 12 h, the whole cell extracts underwent immunoblotting with indicated antibodies. (L) HL-7702/SRE-Luc cells were transfected with HSP90β siRNAs for 48 h, luciferase activity was then measured. (M) 293T cells were transfected with flag-mSREBP-1 and HA-ubiquitin and with or without siRNA HSP90β and FBW7, ubiquitylated SREBP-1 was detected by immunoblot. (N) HL-7702 hepatocytes were transfected with the indicated siRNA for 48 h, the whole cell extracts underwent immunoblotting with indicated antibodies. Error bars are represented as mean ± SEM. Statistical analyses were done with one-way ANOVA (Dunnett\'s post test) (A, C, and E). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 *vs* control siRNA or control vector.](thnov09p5769g003){#F3}

![**Corylin Binds specifically to HSP90β.** (A) Various EGFP-HSP90β truncation mutant plasmids were constructed and the recombination mutant proteins of EGFP-HSP90β were purified. The interaction between different truncated or a triple mutant (W312A, N375A, N436A) form of HSP90β and 17-AAG or corylin was detected by microscale thermophoresis (MST). (B) Molecular docking model of corylin binding to HSP90β. Molecular modeling suggested that corylin binds to a pocket within MD composed of residues 312 to 439. Hydrogen bonds are formed between corylin and W312, N375, N436 of EGFP-HSP90β. (C) Schematic diagram of key structural difference among corylin, compound A and neobavaisoflavone. The interaction between recombination proteins EGFP-HSP90β and corylin, compound A or neobavaisoflavone was detected by microscale thermophoresis (MST).](thnov09p5769g004){#F4}

![**Corylin Inhibits *de novo* Lipids Synthesis by Regulating SREBPs Activity.** (A) HL-7702 cells were treated with HSP90 inhibitors with different structure backbone. Only corylin did not cause cytotoxicity. (B) HL7702 cells were depleted of sterols by incubating in medium D for 24 h, and then switched to medium D containing indicated concentration of corylin for 4 h, or corylin (3 μg/ml) for different time, the whole cell extracts underwent immunoblotting with indicated antibodies. (C-D) HL7702 cells were depleted of sterols by incubating in medium D for 24 h, and then switched to medium D containing 3 µg/ml corylin for 4 h. The expression of various genes was analyzed by qRT-PCR. (E) HL7702 cells were depleted of sterols by incubating in medium D for 24 h, and then switched to medium D containing 3 μg/ml corylin or 2 μM lovastatin for 16 h. Acetic acid sodium salt 1-^14^C was directly added into the medium and incubated for additional 2 h. (F) 293T cells were transfected with Myc-HSP90β and HA-Akt for 24 h, after the treatment, the cells were incubated with medium D containing corylin for another 4 h. Cells were lysed and pulled down by Myc antibody. HL-7702 hepatocytes were treated with GSK3β inhibitor SB216763 (10 µM) (G) or CHIR-9902 (10 µM) (H) for 1 h, the cells were switched to medium D supplemented with inhibitors plus vehicle, or 3 µg/ml corylin for 4 h. The whole cell extracts underwent immunoblotting with indicated antibodies. (I) HL-7702 hepatocytes were transfected with GSK3β siRNA for 48 h, after the treatment, the cells were switched to medium D treated with 3 µg/ml corylin for 4 h. (J) HL-7702 hepatocytes were transfected with HA-Akt for 24 h, after the treatment, the cells were switched to medium D treated with 3 µg/ml corylin for 4 h. Whole cell extracts underwent immunoblotting with indicated antibodies. Error bars are represented as mean ± SEM. Statistical analyses were done with one-way ANOVA (Dunnett\'s post test) (A and C). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 *vs* DMSO.](thnov09p5769g005){#F5}

![**Corylin Improves Lipid Homeostasis in WD-fed mice.** Male C57BL/6J mice at 6 weeks of age were randomly grouped (n=6). Mice were allowed *ad libitum* access to water and different types of diets (WD, western-type diet). Vehicle (0.5% CMC-Na), corylin (15 or 30 mg/kg), or lovastatin (30 mg/kg) was administrated to mice by gastric irrigation every day. After 6 weeks treatment, the mice were sacrificed and subjected to a series of analysis as indicated below. (A) Food intake and body weight. (B) The ratio of fat and body weight or lean. (C) Effect of corylin on serum TG, TC, LDL-c and HDL-c levels. (D) The weight of liver. (E) Effect of corylin on TG and TC levels in the liver. (F) Effect of corylin on Alanine aminotransferase (ALT) and aspartate transaminase (AST) in the serum. (G) Oil red staining in liver and histological analysis of liver, WAT and BAT. Error bars are represented as mean ± SEM. Statistical analyses were done with two-way ANOVA (Bonferroni\'s test) (A) or one-way ANOVA (Dunnett\'s post test) (B-G). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 vs WD.](thnov09p5769g006){#F6}

![**Corylin Decreases the Atherosclerosis Development in ApoE^-/-^ Mice.** Six-week-old male ApoE^-/-^ mice were randomly grouped (n=12) and fed with WD supplemented with vehicle (0.5% CMC-Na), corylin (30mg/kg) or lovastatin (30 mg/kg) for 16 weeks. After the treatment, the mice were sacrificed and subjected to various analyses as described below. (A) Food intake during the 16 weeks experiment period. (B) Body weight of each group during the 16 weeks experiment period. (C) Representative photographs of plasma from each group. (D) The levels of TC, TG, LDL-c and HDL-c in plasma after 16 weeks treatment. (E) Representative photographs from en face analysis of aortas from different groups after 16 weeks treatment. (F-I) Quantification of the lesion areas in (E). (J) qRT-PCR analysis of gene expression in ApoE^-/-^ mice liver after 16 weeks. For each group, equal amounts of total RNA from three mice were subjected to qRT-PCR quantification. Error bars are represented as mean±SEM. Statistical analyses were done with two-way ANOVA (Bonferroni\'s test) (A and B) or one-way ANOVA (Dunnett\'s post test) (D, and F-J). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 vs WD.](thnov09p5769g007){#F7}

[^1]: Competing Interests: There are two pending patent applications of corylin for the treatment of metabolic diseases.
